Skip to main content
S 895 107th Congress Senate Taxation AIDS (Disease) Access to health care Biotechnology Business and social problems Business income tax Clinical trials Commerce Communicable diseases Congress Congressional reporting requirements Developing countries Drug industry Economics and Public Finance Government Operations and Politics Government and business Government trust funds Governmental investigations Health Human immunodeficiency viruses

Vaccines for the New Millennium Act of 2001

Introduced: May 16, 2001 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 107th Congress ended
It never became law before the 107th Congress (2001–2002) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 16, 2001
Read twice and referred to the Committee on Finance.
May 16, 2001
Sponsor introductory remarks on measure. (CR S5008-5009)
May 16, 2001
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service
Vaccines for the New Millennium Act of 2001 - Amends the Internal Revenue Code to allow a limited business credit for the costs medical research related to developing vaccines against widespread diseases. Defines Widespread diseases as malaria, tuberculosis, HIV, or any infectious disease (of a single etiology) which, according to the World Health Organization, causes over one million human deaths annually.

Allows a limited lifesaving vaccine sale credit equal to the amount of qualified vaccine sales. Defines qualified vaccine sales as the aggregate amount paid to the taxpayer for a qualified sale. Defines a qualified sale as a sale of a qualified vaccine: (1) to a nonprofit organization or to a government of any foreign country (or instrumentality of such a government); and (2) for distribution in a developing country.

Establishes the Lifesaving Vaccine Purchase Fund.

Expresses the sense of Congress concerning the manufacture, distribution, support for global efforts, and tiered pricing of vaccines.

What's happening now May 16, 2001

Read twice and referred to the Committee on Finance.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1
D
Murray, Patty
Washington · Nov 5, 2001
Cite this page click to expand
APA
U.S. Congress. (2026). S. 895: Vaccines for the New Millennium Act of 2001. 107th Congress. Open America. https://openamerica.io/bill/107-S-895/
MLA
"S. 895: Vaccines for the New Millennium Act of 2001." 107th Congress, 2026, Open America, https://openamerica.io/bill/107-S-895/.
Bluebook (legal)
S. 895, 107th Cong. (2026), https://openamerica.io/bill/107-S-895/.
Markdown link
[S. 895: Vaccines for the New Millennium Act of 2001](https://openamerica.io/bill/107-S-895/)
Report a problem